01:40 PM EDT, 07/09/2024 (MT Newswires) -- Q32 Bio ( QTTB ) said Tuesday it has completed enrollment in the SIGNAL-AD Phase 2 trial of bempikibart for the treatment of persistent, moderate-to-severe atopic dermatitis in adult patients.

The trial enrolled 121 patients, exceeding the initial target of 100, the firm said. Topline data is expected in Q4.

Price: 18.88, Change: -0.12, Percent Change: -0.63